Ratings Shenyang Xingqi Pharmaceutical Co.,Ltd.

Equities

300573

CNE100002DV1

End-of-day quote Shenzhen S.E. Other stock markets 2024-09-11			5-day change	1st Jan Change
76.28 ^CNY	-0.69%		-5.32%	-41.43%

08-29	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024	CI
08-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

Highlights: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses: Shenyang Xingqi Pharmaceutical Co.,Ltd.

The firm trades with high earnings multiples: 29.66 times its 2024 earnings per share.
The company appears highly valued given the size of its balance sheet.

Ratings Chart: Shenyang Xingqi Pharmaceutical Co.,Ltd.

Source: Surperformance

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-	1.87B
MERCK KGAA		81.29B
KYOWA KIRIN CO. LTD.		12.01B
YUHAN CORPORATION		6.75B
SK BIOPHARMACEUTICALS CO., LTD.		5.83B
BETTA PHARMACEUTICALS CO., LTD.		2.36B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.		1.93B
SUPERNUS PHARMACEUTICALS, INC.	-	1.71B
CHANGCHUN BCHT BIOTECHNOLOGY CO.		1.34B
Average		12.79B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes